LCM
EVLO

Laurion Capital Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Laurion Capital Management’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,130
Closed -$111K – 1227
2020
Q2 		$111K Buy
+1,130
New +$98.9K ﹤0.01% 817
2018
Q3 		– Sell
-7,500
Closed -$1.77M – 1621
2018
Q2 		$1.77M Buy
+7,500
New +$2.19M 0.01% 630

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Laurion Capital Management's EVLO Position: Q3 2020 in Review

Laurion Capital Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q3 2020, closing a stake of 1,130 shares — an estimated $111K sold.

Laurion Capital Management first reported a position in EVLO in Q2 2018 and held it in 2 quarters. The position peaked at $1.77M in Q2 2018. 48 funds tracked by Wall St. Rank hold EVLO as of Q3 2020.

  • Laurion Capital Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Laurion Capital Management sold 1,130 Evelo Biosciences, Inc. Common Stock shares in Q3 2020, an estimated $111K.
  • Laurion Capital Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Laurion Capital Management's Evelo Biosciences, Inc. Common Stock position peaked at $1.77M in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q3 2020.

Based on Laurion Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.